Microvast Holdings announces departure of chief financial officer
Investing.com - CRISPR Therapeutics (NASDAQ:CRSP) maintained its Buy rating from Brookline Capital Markets on Thursday, with the firm reiterating its $268.00 price target following new data for the company’s cardiovascular disease program. The stock, currently trading at $46.60, has shown strong momentum with a 16% return over the past six months, though InvestingPro analysis indicates the stock is trading near its Fair Value.
The latest data release for CTX310 phase I trial showed even higher triglyceride and LDL reductions, reaching 86%, compared to previous topline data released in May 2025. Brookline noted this reinforces the potential of CRISPR’s platform to transform treatment of serious cardiovascular diseases. According to InvestingPro data, the company maintains a healthy financial position with a strong current ratio of 15.64 and more cash than debt on its balance sheet, providing runway for its development programs.
CRISPR Therapeutics expects to present complete CTX310 phase I data at a medical meeting in the second half of 2025. The company believes CTX310, which targets ANGPTL3, has potential for approval based on validated biomarkers, pending regulatory discussions.
The biopharmaceutical company also provided updates on its other cardiovascular programs, including CTX320 targeting the LPA gene. The company now anticipates sharing CTX320 data in the first half of 2026 rather than second half 2025, reflecting a strategic decision based on the evolving Lp(a) treatment landscape.
CRISPR Therapeutics is also advancing CTX340, which targets the AGT gene, as part of its portfolio of in vivo gene-editing treatments aimed at serious cardiovascular diseases.
In other recent news, CRISPR Therapeutics has reported promising Phase 1 clinical data for its experimental cholesterol drug CTX310, highlighting significant reductions in triglycerides and LDL cholesterol levels. The company described the safety profile as well-tolerated and plans to present complete data in the second half of 2025. Additionally, CRISPR Therapeutics has delayed its CTX320 program to incorporate new insights, with data now expected in the first half of 2026. Meanwhile, Chardan Capital Markets has reiterated a buy rating, emphasizing the company’s growing presence in the cardiovascular space. This follows Eli Lilly (NYSE:LLY)’s acquisition of Verve Therapeutics, viewed as a positive signal for gene editing therapies. Barclays (LON:BARC) maintained its Equalweight rating, noting consistent safety results for CTX310. William Blair also reiterated an outperform rating, citing competitive clinical data for CTX310 and potential business development opportunities. Lastly, Citizens JMP reaffirmed its Market Outperform rating, suggesting potential upside as CRISPR Therapeutics advances its in-vivo pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.